Author

P. Bouwman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1 Research Focus:variant calling· 1

Frequent Co-Authors

A. Baze· 1 shared A. Gasparini· 1 shared A. Kersbergen· 1 shared A. Kucukosmanoglu· 1 shared B. van de Water· 1 shared C. Parmentier· 1 shared F. Y. Bois· 1 shared G. Borst· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. Baze

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Transcriptomic mapping of the inter-individual variability of cellular stress response activation in primary human hepatocytes

M. Niemeijer, W. Wiecek, S. Huppelschoten, P. Bouwman, A. Baze, C. Parmentier, L. Richert, R. S. Paules, F. Y. Bois, B. van de Water

The paper maps inter-individual variability in stress response activation in primary human hepatocytes using transcriptome analysis and population modeling to improve DILI prediction.

bioRxiv · Aug 26, 2021 · PreprintPharmacology & Toxicology

Radiosensitivity is an acquired vulnerability of PARPi-resistant BRCA1-deficient tumors

M. Barazas, A. Gasparini, Y. Huang, A. Kucukosmanoglu, S. Annunziato, P. Bouwman, W. Sol, A. Kersbergen, N. Proost, M. van de Ven, J. Jonkers, G. Borst, S. Rottenberg

This study identifies radiotherapy as a therapeutic target for BRCA1-deficient tumors that have developed resistance to PARP inhibitors through 53BP1 pathway inactivation.

bioRxiv · Jul 17, 2018Cancer Biology